OncoMatch/Clinical Trials/NCT06682793
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Is NCT06682793 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies A2B395 for solid tumor, adult.
Treatment: A2B395 — The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC) and other solid tumors that express EGFR and have lost HLA-A\*02 expression. The main questions this study aims to answer are: * Phase 1: What is the recommended dose of A2B395 that is safe for patients * Phase 2: Does the recommended dose of A2B395 kill the solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: * Enrollment in BASECAMP-1 (NCT04981119) * Preconditioning lymphodepletion (PCLD) regimen * A2B395 Tmod CAR T cells at the assigned dose
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Required: HLA-A loss of heterozygosity (LOH) of HLA-A*02
tissue demonstrating LOH of HLA-A*02 by NGS
Required: EGFR expression
solid tumors with EGFR expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: disease-appropriate therapy
Received previous required therapy for the appropriate solid tumor disease as described in the protocol
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplant
Cannot have received: solid organ transplant
Prior solid organ transplant
Lab requirements
Blood counts
adequate organ function as described in the protocol
Kidney function
adequate organ function as described in the protocol
Liver function
adequate organ function as described in the protocol
Has adequate organ function as described in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- UCSD Moores Cancer Center · La Jolla, California
- UCLA Medical Center · Los Angeles, California
- Mayo Clinic · Jacksonville, Florida
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify